Japanese regenerative medicine venture Healios KK and big pharma partner Sumitomo Dainippon Pharma Co. Ltd. (SDP) have reallocated roles and costs under an agreement for a novel cell therapy for age-related macular degeneration (AMD).
Dainippon Partnership Rejig Helps Healios Focus Resources
Big pharma partner takes on prime development responsibility for novel AMD cell therapy as Japanese venture concentrates resources on other in-progress trials.
More from Cell Therapies
More from Advanced Therapies
• By
The company posted positive initial results from the Heart-2 trial in HeFH and CAD, with strong LDL cholesterol lowering and a clean safety profile.
• By
The Swiss major follows Lilly and J&J in committing to a significant spend on US manufacturing.
• By
Adstiladrin sales hit €70m in first full year on the market